CClinicalTrials.gg
Status unknownNCT02321579Updated Dec 22, 2014

Vitamin B-6 and Glutathione on Inflammation, Homocysteine, Oxidative Stress and Antioxidant Capacities

An interventional study of vitamin B-6 and Glutathione in Liver Cirrhosis and Liver Cancer, sponsored by Taichung Veterans General Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-22.

Sponsored by Taichung Veterans General Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This study is designed as a hospital-based cross-sectional and randomized placebo-controlled intervention trial. One hundred and fifty patients with either cirrhosis or cirrhosis combined with hepatocellular carcinoma (HCC) who meet the inclusion criteria will be recruited from Taichung General Veterans Hospital. One hundred patients will be randomly assigned to either the 1) placebo group (n = 25); 2) vitamin B-6 group; (50 mg/d, n = 25); 3) glutathione (GSH) group (500 mg/d, n = 25); or 4) vitamin B-6 (50 mg/d) plus GSH (500 mg/d) group (n = 25) for 3 mo. Data on demography, anthropometry and medical history will be collected. Patients with cirrhosis or cirrhosis combined with HCC will have fasting blood drawn in the clinics. Additionally, patients who participated in the intervention study will have blood drawn at month 0, 1, 2 and 3 during intervention period. Hematological measurements, plasma vitamin B-6 status, GSH, inflammatory markers, homocysteine, cysteine, SAM, SAH, oxidative stress indicator, oxidized GSH and GSH related antioxidant enzyme activities will be analyzed.

Read the detailed description

Liver cirrhosis is now the ninth leading cause of death and hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality among men and women in Taiwan. Vitamin B-6 and glutathione (GSH) are metabolized in liver, the role of vitamin B-6 and GSH playing in the inflammatory responses and antioxidant function would be impaired during hepatic injury. The purpose of this study is going to assess the effects of individual or combined supplementation of vitamin B-6 and GSH on homocysteine, cysteine, the ratio of S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH), oxidative stress, oxidized glutathione (GSSG) and GSH related antioxidant enzyme activities in patients with cirrhosis and cirrhosis combined with HCC.

This study is designed as a hospital-based cross-sectional and randomized placebo-controlled intervention trial. One hundred and fifty patients with either cirrhosis or cirrhosis combined with HCC who meet the inclusion criteria will be recruited from Taichung General Veterans Hospital. One hundred patients will be randomly assigned to either the 1) placebo group (n = 25); 2) vitamin B-6 group; (50 mg/d, n = 25); 3) GSH group (500 mg/d, n = 25); or 4) vitamin B-6 (50 mg/d) plus GSH (500 mg/d) group (n = 25) for 3 mo. Data on demography, anthropometry and medical history will be collected. Patients with cirrhosis or cirrhosis combined with HCC will have fasting blood drawn in the clinics. Additionally, patients who participated in the intervention study will have blood drawn at month 0, 1, 2 and 3 during intervention period. Hematological, plasma vitamin B-6 status, GSH, inflammatory markers, homocysteine, cysteine, SAM, SAH, oxidative stress indicator, GSSG and GSH related antioxidant enzyme activities will be measured.

Hopefully, the results of this study could provide more pictures on the beneficial effects of vitamin B-6 and GSH supplementation on inflammatory responses, homocysteine, cysteine, the ratio of SAM/SAH, oxidative stress, GSSG and GSH related antioxidant enzyme activities in patients with cirrhosis and HCC.

02

Conditions studied

  • Liver Cirrhosis
  • Liver Cancer
03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's planned enrollment of 25 is below the median of 72 across 995 interventional studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Taichung Veterans General Hospital is the lead sponsor of 171 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age between 20 to 80 years old
  2. patients are diagnosed as cirrhosis or cirrhosis combined with hepatocellular carcimoma

Exclusion criteria

Exclusion Criteria:

  1. patients are currently taking any nutrient supplements
  2. patients with cardiac, renal, gastrointestinal or diabetic diseases
  3. patients are currently taking any medication which will interfere with vitamin B-6 or glutathione metabolism〔i.e., phenobarbital, phenytoin, cycloserine, pyrazinamide, isoniazid, (thio)semicarbazide, hydramitrazine, phenelzine, carbidopa, levodopa, hydralazine, steroids and penicillamine)
  4. patients are in pregnant or lactation.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
25 participants (estimated)

Study arms

  • Placebo comparator
    Negative control

    Dextrins

    Dietary Supplement: Dextrins

  • Experimental
    Supplement 1

    50 mg/d vitamin B-6

    Dietary Supplement: vitamin B-6

  • Experimental
    Supplement 2

    500 mg/d Glutathione

    Dietary Supplement: Glutathione

  • Experimental
    Supplement 3

    50 mg/d vitamin B-6 plus 500 mg/d Glutathione

    Dietary Supplement: vitamin B-6 · Dietary Supplement: Glutathione

Interventions

  • Dietary supplementvitamin B-6

    50 mg/d

  • Dietary supplementGlutathione

    500 mg/d

  • Dietary supplementDextrins

    50 mg/d

06

What researchers measure

Primary outcomes

  1. Oxidative stress marker (MDA concentation)

    Time frame: 3 months

Secondary outcomes

  1. Glutathione related enzyme activities

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
    • Yi-Chia Huang, PhD · Contact · ych@csmu.edu.tw · +886-4-24730022
    • Shao-Bin Cheng, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02321579
Lead sponsor
Taichung Veterans General Hospital
Responsible party
Sponsor
First posted
Dec 22, 2014
Start date
Dec 2014
Primary completion
Dec 2016 (estimated)
Completion
Jul 2017 (estimated)
Last update
Dec 22, 2014

Study contacts

Yi-Chia Huang, PhD
Contact
ych@csmu.edu.tw
+886-4-24730022 ext. 12198
Shao-Bin Cheng, MD
principal investigator · Taichung Veterans General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion